KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCvaccines Revenue BreakdownDeferred RevenueEbt By SegmentEbt Margin By Segment %Employee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %Hospital Revenue BreakdownIncome Before Income TaxInflammation And Immunology Revenue BreakdownInternal Medicine Revenue BreakdownInventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue BreakdownOperating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment SegregationRare Disease Revenue BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical Annual %Revenue By Customer GroupRevenue By Customer Group %Revenue By Products AnnualaRevenue By Products Annuala %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Therapeutic Area AnnualRevenue By Therapeutic Area Annual %Revenue By WholesalersRevenue By Wholesalers %U.S Revenue By Wholesalers %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Gross Profit (2019 - 2024)

Pfizer has reported Gross Profit over the past 18 years, most recently at -$1.2 billion for Q1 2026.

  • Quarterly Gross Profit fell 65.16% to -$1.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.7 billion through Mar 2026, down 51.68% year-over-year, with the annual reading at $46.5 billion for FY2025, 591.51% up from the prior year.
  • Gross Profit was -$1.2 billion for Q1 2026 at Pfizer, down from $12.3 billion in the prior quarter.
  • Over five years, Gross Profit peaked at $19.1 billion in Q3 2022 and troughed at -$7.6 billion in Q4 2023.
  • The 5-year median for Gross Profit is -$732.0 million (2025), against an average of $4.1 billion.
  • Year-over-year, Gross Profit crashed 146.0% in 2023 and then skyrocketed 3845.85% in 2024.
  • A 5-year view of Gross Profit shows it stood at $16.6 billion in 2022, then plummeted by 124.91% to -$4.1 billion in 2023, then decreased by 16.76% to -$4.8 billion in 2024, then skyrocketed by 354.82% to $12.3 billion in 2025, then tumbled by 109.84% to -$1.2 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Gross Profit are -$1.2 billion (Q1 2026), $12.3 billion (Q4 2025), and -$1.9 billion (Q3 2025).